Hepatitis C This is an OPML file. It can be used to export all the MedWorm RSS feeds on this topic into your personal RSS reader (usually you have to save this file to your own computer before clicking on an Import OPML command in your own feed reader to upload the file which will then import all the feeds) or it can be used by webmasters to integrate MedWorm feeds with their own website. This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

This page shows you the latest news and research items in this category.

International Medical News from Johns Hopkins (with audio)
(MedPage Today) -- This month's topics include eating insects, a significant reduction in childhood mortality, a new drug to combat hepatitis C and ways to prevent malaria. (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - June 16, 2013 Category: Pediatrics Source Type: news

[Comment] Hepatitis C treatment: interferon free or interferon freer?
Pegylated interferon alfa-2a (peginterferon) and ribavirin are the standard of care for all six genotypes of hepatitis C virus. Hepatitis C virus (HCV) does not integrate into the human genome. Thus a sustained virological response (SVR) is tantamount to virological cure and reduces the likelihood of progressive liver disease. About 45% of patients with HCV genotype-1 achieve SVR. Single nucleotide polymorphisms in the human genome affect response to interferon. However, patients with cirrhosis have lower response rates. (Source: LANCET)
Source: LANCET - June 15, 2013 Category: Journals (General) Authors: Geoffrey Dusheiko, Tabinda Burney Tags: Comment Source Type: research

[Articles] Sofosbuvir with pegylated interferon alfa-2a and ribavirin for treatment-naive patients with hepatitis C genotype-1 infection (ATOMIC): an open-label, randomised, multicentre phase 2 trial
Our findings suggest that sofosbuvir is well tolerated and that there is no additional benefit of extending treatment beyond 12 weeks, but these finding will have to be substantiated in phase 3 trials. These results lend support to the further assessment of a 12 week sofosbuvir regimen in a broader population of patients with chronic HCV genotype-1 infection, including those with cirrhosis. (Source: LANCET)
Source: LANCET - June 15, 2013 Category: Journals (General) Authors: Kris V Kowdley, Eric Lawitz, Israel Crespo, Tarek Hassanein, Mitchell N Davis, Michael DeMicco, David E Bernstein, Nezam Afdhal, John M Vierling, Stuart C Gordon, Jane K Anderson, Robert H Hyland, Hadas Dvory-Sobol, Di An, Robert G Hindes, Efsevia Albanis Tags: Articles Source Type: research

Interferon/Ribavirin Treatment for HCV Is Associated with the Development of Hypophosphatemia in HIV/Hepatitis C Virus-Coinfected Patients
AIDS Research and Human Retroviruses , Vol. 0, No. 0. (Source: AIDS Research and Human Retroviruses)
Source: AIDS Research and Human Retroviruses - June 14, 2013 Category: Infectious Diseases Tags: article Source Type: research

Old Bones Give Clues to Leprosy's Demise in Europe
Title: Old Bones Give Clues to Leprosy's Demise in EuropeCategory: Health NewsCreated: 6/13/2013 2:36:00 PMLast Editorial Review: 6/14/2013 12:00:00 AM (Source: MedicineNet Hepatitis C General)
Source: MedicineNet Hepatitis C General - June 14, 2013 Category: Infectious Diseases Source Type: news

The changing face of the ‘royal disease’ – Medicolegal aspects of haemophilia
Abstract: Haemophilia represents a group of heritable disorders caused by deficiencies in plasma proteins that are involved in coagulation. The case of a two-year-old boy with an established diagnosis of haemophilia B is reported to demonstrate a rare cause of unexpected death. He had a recent history of epistaxis and was found unexpectedly dead. At autopsy the posterior pharynx was obstructed by blood clot with aspirated blood within the distal airways of the lungs, and melena throughout both small and large intestines. His death was due to haemorrhage and airway obstruction complicating epistaxis. The profile of individu...
Source: Journal of Forensic and Legal Medicine - June 14, 2013 Category: Forensic Medicine Authors: Roger W. Byard Tags: Case Reviews Source Type: research

Serum autoantibodies positivity prevalence in patients with chronic HCV and impact on pegylated interferon and ribavirin treatment response
ConclusionsANA positivity is not a factor in chronic HCV disease progression and does not affect the treatment response. Pegylated interferon and ribavirin therapy is safe and effective in autoantibodies‐positive chronic HCV patients with no need for further follow‐up or worry during the treatment in absence of systemic autoimmune disorders. (Source: Liver International)
Source: Liver International - June 14, 2013 Category: Gastroenterology Authors: Marwa Khairy, Maissa El‐Raziky, Wafaa El‐Akel, Mohamed S. Abdelbary, Hany Khatab, Badawy El‐Kholy, Gamal Esmat, Mahassen Mabrouk Tags: Viral Hepatitis Source Type: research

The AASLD clinical practice guidelines: A critical review of scientific evidence and evolving recommendations
Conclusions:Despite significant increases in the numbers of recommendations within AASLD practice guidelines over time, only a minority are supported by grade I evidence, highlighting the need for developing well‐designed investigations to provide evidence for areas of uncertainty and improving the quality of future guidelines in hepatobiliary diseases. (HEPATOLOGY 2013.) (Source: Hepatology)
Source: Hepatology - June 14, 2013 Category: Internal Medicine Authors: Christopher Koh, Xiongce Zhao, Niharika Samala, Sasan Sakiani, T. Jake Liang, Jayant A. Talwalkar Tags: Clinical Observations in Hepatology Source Type: research

Hepatitis C virus transmission risk in incarcerated or detained populations: Authors' reply
(Source: Hepatology)
Source: Hepatology - June 14, 2013 Category: Internal Medicine Authors: Sarah Larney, Nickolas D. Zaller, Louisa Degenhardt Tags: Correspondence Source Type: research

Hepatitis C virus transmission risk in incarcerated or detained populations
(Source: Hepatology)
Source: Hepatology - June 14, 2013 Category: Internal Medicine Authors: Ethan K. Gough, Mirjam‐Colette Kempf, Eric Chamot Tags: Correspondence Source Type: research

Isolate‐dependent use of Claudins for cell entry by hepatitis C virus
Conclusion: These findings highlight differential CLDN usage by HCV isolates which may evolve based on variable expression of CLDN proteins in human liver cells. Broad CLDN tropism may facilitate viral escape from CLDN1‐specific therapeutic strategies. (HEPATOLOGY 2013.) (Source: Hepatology)
Source: Hepatology - June 14, 2013 Category: Internal Medicine Authors: Sibylle Haid, Christina Grethe, Michael T. Dill, Markus Heim, Lars Kaderali, Thomas Pietschmann Tags: Viral Hepatitis Source Type: research

Paracrine signals from liver sinusoidal endothelium regulate hepatitis C virus replication
Conclusion: These studies identify a role for LSEC and BMP4 in HCV infection and highlight BMP4 as a new therapeutic target for treating individuals with liver disease. (HEPATOLOGY 2013.) (Source: Hepatology)
Source: Hepatology - June 14, 2013 Category: Internal Medicine Authors: Ian A Rowe, Sukhdeep K Galsinh, Garrick K Wilson, Richard Parker, Sarah Durant, Catalin Lazar, Norica Branza‐Nichita, Roy Bicknell, David H Adams, Peter Balfe, Jane A McKeating Tags: Viral Hepatitis Source Type: research

Human serum leads to differentiation of human hepatoma cells, restoration of VLDL secretion and a 1000‐fold increase in HCV JFH‐1 titers
In this study we differentiated the human hepatoma cell line Huh7.5 by supplementing tissue culture media with human serum (HS), and examined the production of hepatitis C virus by these cells. We compared the standard tissue culture protocol, using media supplemented with 10% fetal bovine serum (FBS), to media supplemented with 2% HS. Cells cultured in HS undergo rapid growth arrest, have a hepatocyte‐like morphology, and increased the expression of hepatocyte differentiation markers. In addition, expression of cell adhesion proteins claudin‐1, occludin and e‐cadherin are also increased. The lipid droplet content of...
Source: Hepatology - June 14, 2013 Category: Internal Medicine Authors: Rineke H.G. Steenbergen, Michael A. Joyce, Bradley S. Thomas, Daniel Jones, John Law, Rodney Russell, Michael Houghton, D. Lorne Tyrrell Tags: Viral Hepatitis Source Type: research

Polymorphisms of the core, NS3, and NS5A proteins of hepatitis C virus genotype 1b associate with development of hepatocellular carcinoma
Conclusion: HCV isolates with core‐Gln70 and/or NS3‐Tyr1082/Gln1112 are more closely associated with HCC development compared to those with non‐(Gln70 plus NS3‐Tyr1082/Gln1112). (HEPATOLOGY 2013) (Source: Hepatology)
Source: Hepatology - June 14, 2013 Category: Internal Medicine Authors: Ahmed El‐Shamy, Michiko Shindo, Ikuo Shoji, Lin Deng, Tadao Okuno, Hak Hotta Tags: Viral Hepatitis Source Type: research

Hepatitis B and C virus infection among hemodialysis patients in yogyakarta, Indonesia: Prevalence and molecular evidence for nosocomial transmission
Abstract Hemodialysis patients are at an increased risk of acquiring hepatitis B virus (HBV) and hepatitis C virus (HCV) infection. However, the prevalence of hepatitis viral infection and its genotype distribution among hemodialysis patients in Indonesia are unclear. In order to investigate these issues and the possibility of nosocomial transmission, 161 hemodialysis patients and 35 staff members at one of the hemodialysis unit in Yogyakarta, Indonesia, were tested for serological and virological markers of both viruses. HBV surface antigen (HBsAg) was detected in 18 patients (11.2%) and in two staff members (5.7%). Anti�...
Source: Journal of Medical Virology - June 13, 2013 Category: Virology Authors: Hanggoro Tri Rinonce, Yoshihiko Yano, Takako Utsumi, Didik Setyo Heriyanto, Nungki Anggorowati, Dewiyani Indah Widasari, Maria Inge Lusida,   Soetjipto, Heru Prasanto, Hak Hotta, Yoshitake Hayashi Tags: Research Article Source Type: research

Multicenter evaluation of the elecsys® anti‐HCV II assay for the diagnosis of hepatitis C virus infection
In conclusion, the Elecsys® Anti‐HCV II assay is a sensitive and specific assay suitable for routine use in the reliable detection of anti‐HCV antibodies. J. Med. Virol. 85:1362–1368, 2013. © 2013 Wiley Periodicals, Inc. (Source: Journal of Medical Virology)
Source: Journal of Medical Virology - June 13, 2013 Category: Virology Authors: Juan I. Esteban, Josef van Helden, Flora Alborino, Philippe Bürgisser, Cristina Cellerai, Giuseppe Pantaleo, Adolfo Eiras, Maria I. Rodriguez, Valeria Ghisetti, Michael Gleich, Roland Imdahl, Claudia Kaiser, Petra Möller, Olaf Wetlitzky, Manuel Segovia, Tags: Research Article Source Type: research

Experiences and Perceptions of Patients Living With Hepatitis C in Karachi, Pakistan
Conclusion and implications for practice: Patients with HCV experience profound challenges that are influenced by their level of education, financial capacity, cultural norms, family support, and the sensitivity of health care professionals. Several cultural practices existing in Pakistan identify the need for public awareness. The findings on health care professionals have implications for nursing and allied health continuing education. (Source: Journal of Transcultural Nursing)
Source: Journal of Transcultural Nursing - June 13, 2013 Category: Nursing Authors: Jiwani, N. S., Gul, R. B., Ali, A., Salih, M., Hanzala, M. Tags: Research Department Source Type: research

Disruption Of Iron Uptake Receptor Identified In Hepatitis C
Hepatitis C virus (HCV) infects more than 170 million people worldwide. Approximately 80 percent of infections lead to chronic illness including fibrosis, cirrhosis, cancer and also hepatic iron overload. A new study completed by researchers at Loyola University Chicago Stritch School of Medicine reveals that HCV not only alters expression of the iron-uptake receptor known as transferrin receptor 1 (TfR1) but that TfR1 also mediates HCV entry... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 12, 2013 Category: Consumer Health News Tags: Liver Disease / Hepatitis Source Type: news

CDC: 87 Now Sickened in Hepatitis A Outbreak Tied to Frozen Berry Mix
Title: CDC: 87 Now Sickened in Hepatitis A Outbreak Tied to Frozen Berry MixCategory: Health NewsCreated: 6/11/2013 12:35:00 PMLast Editorial Review: 6/12/2013 12:00:00 AM (Source: MedicineNet Hepatitis C General)
Source: MedicineNet Hepatitis C General - June 12, 2013 Category: Infectious Diseases Source Type: news

Faldaprevir combined with pegylated interferon alfa‐2a and ribavirin in treatment‐naïve patients with chronic genotype1 HCV: SILEN‐C1 trial
Conclusion: Faldaprevir QD with PegIFN/RBV achieved consistently high SVR rates with acceptable tolerability and safety at all dose levels. The 120 and 240 mg QD doses are currently undergoing phase 3 evaluation. (HEPATOLOGY 2013;57:2143–2154) (Source: Hepatology)
Source: Hepatology - June 12, 2013 Category: Internal Medicine Authors: Mark S. Sulkowski, Tarik Asselah, Jacob Lalezari, Peter Ferenci, Hugo Fainboim, Barbara Leggett, Fernando Bessone, Stefan Mauss, Jeong Heo, Yakov Datsenko, Jerry O. Stern, George Kukolj, Joseph Scherer, Gerhard Nehmiz, Gerhard G. Steinmann, Wulf O. Böche Tags: Viral Hepatitis Source Type: research

Faldaprevir combined with peginterferon alfa‐2a and ribavirin in chronic hepatitis C virus genotype‐1 patients with prior nonresponse: SILEN‐C2 trial
Conclusion: Faldaprevir 240 mg QD with PegIFN/RBV was safe and tolerable and produced substantial SVR rates in prior null and partial responders. The 240 mg QD dose is currently undergoing phase 3 evaluation. (Hepatology 2013;57:2155–2163) (Source: Hepatology)
Source: Hepatology - June 12, 2013 Category: Internal Medicine Authors: Mark S. Sulkowski, Marc Bourlière, Jean‐Pierre Bronowicki, Tarik Asselah, Jean‐Michel Pawlotsky, Stephen D. Shafran, Stanislas Pol, Stefan Mauss, Dominique Larrey, Yakov Datsenko, Jerry O. Stern, George Kukolj, Joseph Scherer, Gerhard Nehmiz, Gerhard Tags: Viral Hepatitis Source Type: research

Selenium levels in patients with hepatitis C virus‐related chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma: A pilot study
(Source: Hepatology)
Source: Hepatology - June 12, 2013 Category: Internal Medicine Authors: Dominik Bettinger, Michael Schultheiss, Nadine Hennecke, Elisabeth Panther, Eva Knüppel, Hubert E. Blum, Robert Thimme, Hans Christian Spangenberg Tags: Correspondence Source Type: research

Nutritional status of patients with alcoholic cirrhosis undergoing liver transplantation: time trends and impact on survival
Summary Alcoholic cirrhotics evaluated for liver transplantation are frequently malnourished or obese. We analyzed alcoholic cirrhotics undergoing transplantation to examine time trends of nutrition/weight, transplant outcome, and effects of concomitant hepatitis C virus (HCV) and/or hepatocellular carcinoma (HCC). Nutrition and transplant outcomes were reviewed for alcoholic cirrhosis with/without HCV/HCC. Malnutrition was defined by subjective global assessment. Body mass index (BMI) classified obesity. A total of 261 patients receiving transplants were separated (1988–2000, 2001–2006, and 2007–2011) to generate si...
Source: Transplant International - June 11, 2013 Category: Transplant Surgery Authors: Ashwani K. Singal, Patrick S. Kamath, Nickie Francisco Ziller, Sara DiCecco, M. Shoreibah, Walter Kremers, Michael R. Charlton, Julie K. Heimbach, Kymberly D. Watt, Vijay H. Shah Tags: Original Article Source Type: research

Jiangsu CTTQ to develop and commercialise BioLineRx's Hepatitis C drug
Biopharmaceutical development company BioLineRx has collaborated with Chinese pharmaceutical company Jiangsu Chia-tai Tianqing Pharmaceutical (CTTQ) to develop and commercialise oral hepatitis C drug BL-8030. (Source: Drug Development Technology)
Source: Drug Development Technology - June 10, 2013 Category: Pharmaceuticals Source Type: news

Virus-Neutralizing Antibodies to Hepatitis C VirusVirus-Neutralizing Antibodies to Hepatitis C Virus
Will new research in the adaptive immune response help scientists develop a vaccine against hepatitis C? Journal of Viral Hepatitis (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 10, 2013 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news

Antiviral agents: structural basis of action and rational design.
Abstract During the last 30 years, significant progress has been made in the development of novel antiviral drugs, mainly crystallizing in the establishment of potent antiretroviral therapies and the approval of drugs inhibiting hepatitis C virus replication. Although major targets of antiviral intervention involve intracellular processes required for the synthesis of viral proteins and nucleic acids, a number of inhibitors blocking virus assembly, budding, maturation, entry or uncoating act on virions or viral capsids. In this review, we focus on the drug discovery process while presenting the currently used metho...
Source: Sub-Cellular Biochemistry - June 10, 2013 Category: Biochemistry Authors: Menéndez-Arias L, Gago F Tags: Subcell Biochem Source Type: research

New Loyola study on hepatitis C virus entry factor
(Loyola University Health System) A new study completed by researchers at Loyola University Chicago Stritch School of Medicine reveals that HCV not only alters expression of the iron-uptake receptor known as transferrin receptor 1 (TfR1), but that TfR1 also mediates HCV entry. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - June 10, 2013 Category: Global & Universal Source Type: news

Somatic hypermutations confer rheumatoid factor activity in hepatitis C virus‐associated mixed cryoglobulinemia
Conclusion. SHM significantly contributes to RF activity in HCV MC patients, suggesting that autoreactivity in these patients arises through antigen‐dependent SHM, as opposed to non‐deletion of autoreactive germline Igs. © 2013 American College of Rheumatology. (Source: Arthritis and Rheumatism)
Source: Arthritis and Rheumatism - June 10, 2013 Category: Rheumatology Authors: Edgar D. Charles, Michael I. M. Orloff, Eiko Nishiuchi, Svetlana Marukian, Charles M. Rice, Lynn B. Dustin Tags: Full Length Source Type: research

All‐oral, interferon‐free treatment for chronic hepatitis C: cost‐effectiveness analyses
Summary Interferon‐based standard of care treatments (SOC) for chronic hepatitis C are unable to provide high cure rates in certain subgroups of the infected population and can cause debilitating side effects. Clinical trials evaluating all‐oral, interferon‐free treatments have demonstrated high rates of sustained virologic response with no resistance or major adverse events in most populations. As these drug regimens move towards FDA approval, it will be important to assess their cost‐effectiveness in addition to their clinical efficacy. A decision‐analytic Markov model with a lifetime, societal perspective was ...
Source: Journal of Viral Hepatitis - June 10, 2013 Category: Infectious Diseases Authors: L. M. Hagan, Z. Yang, M. Ehteshami, R. F. Schinazi Tags: Original Article Source Type: research

FDA Grants Priority Review For The Hepatitis C Drug "Sofosbuvir"
The U.S. Food and Drug Adminstration (FDA) has just granted priority review to Gilead Sciences Inc.'s latest New Drug Application (NDA) for "Sofosbuvir", an experimental drug candidate for the treatment of hepatitis C. On April 8, 2013 the company filed the NDA for review and the FDA has determined a target review date under the Prescription Drug User Fee Act of December 8... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - June 9, 2013 Category: Consumer Health News Tags: Regulatory Affairs / Drug Approvals Source Type: news

Sustained virological response following chronic hepatitis C treatment is associated with improvement in insulin resistance
ConclusionsHepatitis C virus clearance is associated with improvement in IR. Although baseline hepatic fibrosis is a predictor of IR, changes in IR appear to be independent of changes in liver fibrosis. Treatment‐related improvement in gamma‐glutamyl transpeptidase and alanine aminotransferase seen with improved IR may be a possible marker of reduction of hepatic oxidative stress. (Source: Internal Medicine Journal)
Source: Internal Medicine Journal - June 9, 2013 Category: Internal Medicine Authors: C. H. Y. Chan, R. D. Hansen, R. S. Gilliver, B. E. Jones Tags: Original Article Source Type: research

Hepatitis B and C in Switzerland - healthcare provider initiated testing for chronic hepatitis B and C infection.
Abstract Hepatitis B and hepatitis C are contagious liver diseases caused by the hepatitis B virus (HBV) and the hepatitis C virus (HCV), respectively. In particular, chronic infection with HBV or HCV is a major public health problem throughout Europe. The majority of persons chronically infected (65%-75%) are not aware of their infection status until symptoms of advanced liver disease appear. In addition, the peak in the number of patients suffering from advanced stages of the disease, such as cirrhosis and hepatocellular carcinoma, has not yet been reached. In order to reduce the current and future morbidity and ...
Source: Swiss Medical Weekly - June 8, 2013 Category: Journals (General) Authors: Fretz R, Negro F, Bruggmann P, Lavanchy D, De Gottardi A, Pache I, Masserey Spicher V, Cerny A Tags: Swiss Med Wkly Source Type: research

Richard Branson says decriminalising drugs would not lose votes
Virgin boss says MPs must be brave and not send addicts to jailSir Richard Branson has called on politicians to "be braver" on drugs policy, saying they are wrong to believe decriminalisation would be a vote-loser.Speaking on the eve of a major international drugs conference, Branson said that, if politicians acted on what they really believed rather than following a Daily Mail agenda, they could reduce a "ballooning" prison population exacerbated by excessive numbers of convictions for low-level drugs offences.Branson, who is to give a video address at the opening of the International Harm Reduction Conference (IHRC) in V...
Source: Guardian Unlimited Science - June 8, 2013 Category: Science Authors: Mary O'Hara Tags: Richard Branson News Zac Goldsmith Drugs David Nutt Caroline Lucas Politics UK news Drugs policy The Observer Source Type: news

The safety profile of ustekinumab in the treatment of psoriasis patients with concurrent hepatitis B or hepatitis C
ConclusionAntiviral prophylaxis appears to minimize the risk of viral reactivation in patients with concurrent psoriasis and HBV. Without effective antiviral prophylaxis, the risk /benefit of ustekinumab treatment should be carefully assessed in psoriasis patients with HBV, HCV and/or HCC. A close monitoring for HBV and HCV viral load is recommended, particularly for patients with high risk factors. Serum aminotransferase determination may not be useful for early detection of viral reactivation.This article is protected by copyright. All rights reserved. (Source: British Journal of Dermatology)
Source: British Journal of Dermatology - June 8, 2013 Category: Dermatology Authors: H.‐Y. Chiu, C.‐H. Chen, M.‐S. Wu, Y.‐P. Cheng, T.‐F. Tsai Tags: Original Article Source Type: research

The safety profile of ustekinumab in the treatment of psoriasis patients with concurrent hepatitis B or hepatitis C.
CONCLUSION: Antiviral prophylaxis appears to minimize the risk of viral reactivation in patients with concurrent psoriasis and HBV. Without effective antiviral prophylaxis, the risk /benefit of ustekinumab treatment should be carefully assessed in psoriasis patients with HBV, HCV and/or HCC. A close monitoring for HBV and HCV viral load is recommended, particularly for patients with high risk factors. Serum aminotransferase determination may not be useful for early detection of viral reactivation. This article is protected by copyright. All rights reserved. PMID: 23746170 [PubMed - as supplied by publisher] (Source: Th...
Source: The British Journal of Dermatology - June 8, 2013 Category: Dermatology Authors: Chiu HY, Chen CH, Wu MS, Cheng YP, Tsai TF Tags: Br J Dermatol Source Type: research

FDA grants priority review status to Gilead's hepatitis C drug
(Reuters) - Biotechnology company Gilead Sciences Inc said the U.S. Food and Drug Administration (FDA) granted priority review to its experimental hepatitis C drug sofosbuvir. (Source: Reuters: Health)
Source: Reuters: Health - June 7, 2013 Category: Consumer Health News Tags: healthNews Source Type: news

Vitamins: stop taking the pills
This article was corrected on 7 June 2013. During editing, a line in the fifth from last paragraph, beginning 'Another example is St John's wort…' was accidentally transposed, leading to the suggestion that serotonin was a medicine rather than a brain chemical.Alternative medicineHealth & wellbeingHealthCancerCancerMedical researchPharmaceuticals industryDepressionguardian.co.uk © 2013 Guardian News and Media Limited or its affiliated companies. All rights reserved. | Use of this content is subject to our Terms & Conditions | More Feeds (Source: Guardian Unlimited Science)
Source: Guardian Unlimited Science - June 7, 2013 Category: Science Tags: The Guardian Depression Pharmaceuticals industry Health Medical research & wellbeing Society Extracts Features Cancer Life and style Alternative medicine Science Source Type: news

MERS Virus May Never Become Big Threat in U.S., Experts Say
Title: MERS Virus May Never Become Big Threat in U.S., Experts SayCategory: Health NewsCreated: 6/6/2013 12:35:00 PMLast Editorial Review: 6/7/2013 12:00:00 AM (Source: MedicineNet Hepatitis C General)
Source: MedicineNet Hepatitis C General - June 7, 2013 Category: Infectious Diseases Source Type: news

A multicentre survey of hepatitis C awareness in a high‐risk population
ConclusionsAwareness of HCV infection status in this high‐risk population is suboptimal. This indicates that existing educational strategies are inadequate and that there is a disconnect between their health needs and the medical care they receive. Novel approaches need to be considered to improve the knowledge of HCV transmission and hopefully improve HCV‐associated health outcomes in high‐risk populations. (Source: Journal of Paediatrics and Child Health)
Source: Journal of Paediatrics and Child Health - June 7, 2013 Category: Pediatrics Authors: Therese Kanaan, Anthony Liu, Marcel Leroi, Ralph Nanan Tags: Original Article Source Type: research

Treatment of hepatitis C in compensated cirrhotic patients is equally effective before and after liver transplantation.
CONCLUSION: HCV antiviral treatment is equally effective in compensated cirrhotics both before and after LT, which patients show a higher risk of premature treatment withdrawal and a reduced survival, independently of the achievement of SVR. PMID: 23745027 [PubMed - in process] (Source: World Journal of Gastroenterology)
Source: World Journal of Gastroenterology - June 7, 2013 Category: Gastroenterology Authors: Ponziani FR, Annicchiarico EB, Siciliano M, D'Aversa F, Pompili M, Gasbarrini A Tags: World J Gastroenterol Source Type: research

Epidemiology, clinical-treatment patterns and outcome in 256 hepatocellular carcinoma cases.
CONCLUSION: This study showed that, between 2000-2005 and 2005-2010, the number of HCV-related HCC decreased, non-viral/non alcoholic etiologies increased and of surveillance programs were more frequently applied. PMID: 23745022 [PubMed - in process] (Source: World Journal of Gastroenterology)
Source: World Journal of Gastroenterology - June 7, 2013 Category: Gastroenterology Authors: Fenoglio L, Serraino C, Castagna E, Cardellicchio A, Pomero F, Grosso M, Senore C Tags: World J Gastroenterol Source Type: research

Sofosbuvir and ABT-450: Terminator of hepatitis C virus?
Abstract Combination therapy with peginterferon (pegIFN)-α and ribavirin (RBV) has been the standard of care (SOC) for chronic hepatitis C. Unfortunately, not all patients can achieve a sustained virologic response (SVR) with this regimen. SVR rates are approximately 80% in patients with hepatitis C virus (HCV) genotype 2, 3, 5 and 6 and 40%-50% in patients with genotype 1 and 4. Therefore, strategies to improve SVR rates have been an important issue for clinical physicians. Several direct acting antiviral agents (DAAs) have significantly higher SVR rates when combined with pegIFN-α and RBV than pegIFN-α and RBV...
Source: World Journal of Gastroenterology - June 7, 2013 Category: Gastroenterology Authors: Zeng QL, Zhang JY, Zhang Z, Wang LF, Wang FS Tags: World J Gastroenterol Source Type: research

Acetylation Regulates REG{gamma} Heptamerization and Activity [Cell Biology]
In this study, we report for the first time that REGγ can be acetylated mostly on its lysine 195 (Lys-195) residue by CREB binding protein (CBP), which can be reversed by sirtuin 1 (SIRT1) in mammalian cells. Site-directed mutagenesis abrogated acetylation at Lys-195 and significantly attenuated the capability of REGγ to degrade its target substrates, p21 and hepatitis C virus core protein. Mechanistically, acetylation at Lys-195 is important for the interactions between REGγ monomers and ultimately influences REGγ heptamerization. Biological analysis of cells containing REGγ-WT or REGγ-K195R mutant indicates an impa...
Source: Journal of Biological Chemistry - June 7, 2013 Category: Chemistry Authors: Liu, J., Wang, Y., Li, L., Zhou, L., Wei, H., Zhou, Q., , Wang, W., Ji, L., Shan, P., , Yang, Y., Jung, S. Y., Zhang, P., Wang, C., Long, W., Zhang, B., Li, X. Tags: Gene Regulation Source Type: research

Epidemiology of hepatitis B and hepatitis C virus infections in pregnant women in Sana'a, Yemen
Conclusion: The results of this study suggest that HBsAg and anti-HCV have high prevalence among pregnant women. (Source: BMC Pregnancy and Childbirth - Latest articles)
Source: BMC Pregnancy and Childbirth - Latest articles - June 7, 2013 Category: OBGYN Authors: Entisar MuradSuad BabikerGasim GasimDuria RayisIshag Adam Source Type: research

Unusual oral mucosa damage during telaprevir treatment of chronic hepatitis C
(Source: Hepatology)
Source: Hepatology - June 7, 2013 Category: Internal Medicine Authors: Vasily Isakov, Sergey Morozov, Laurence Valeyrie‐Allanore Tags: Viral Hepatitis Source Type: research

Epidemiology of hepatitis B and hepatitis C virus infections in pregnant women in Sana¿a, Yemen
Conclusion: The results of this study suggest that HBsAg and anti-HCV have high prevalence among pregnant women. (Source: BMC Pregnancy and Childbirth - Latest articles)
Source: BMC Pregnancy and Childbirth - Latest articles - June 7, 2013 Category: OBGYN Authors: Entisar MuradSuad BabikerGasim GasimDuria RayisIshag Adam Source Type: research

Hepatitis C: The Pace of ProgressHepatitis C: The Pace of Progress
Advanced understanding of hepatitis C continues to bring new targeted therapies that might be better tolerated by patients. Medscape Gastroenterology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 6, 2013 Category: Consumer Health News Tags: Gastroenterology Commentary Source Type: news

Primary Efficacy and Safety Findings from Four Phase 3 Japanese Studies of Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Genotype 1 Chronic Hepatitis C Adult Patients (Jun 6, 2013)
CORK, Ireland (June 6, 2013) -- Janssen R&D Ireland (Janssen) today announced primary efficacy and safety results from four Japanese Phase 3 clinical studies demonstrating that the use of the investigational NS3/4A protease inhibitor simeprevir (TMC435) led to sustained virologic response 12 weeks after the end of treatment (SVR12) in patients with genotype 1 hepatitis C, when administered once daily with pegylated interferon and ribavirin. The four studies examined the use of simeprevir in patients who were treatment na?ve, as well as patients who were non-responders to prior therapy or relapsed following treatment wi...
Source: Johnson and Johnson - June 6, 2013 Category: Pharmaceuticals Source Type: news

Men Face Higher Risk of Infections Related to Health Care
Title: Men Face Higher Risk of Infections Related to Health CareCategory: Health NewsCreated: 6/5/2013 12:35:00 PMLast Editorial Review: 6/6/2013 12:00:00 AM (Source: MedicineNet Hepatitis C General)
Source: MedicineNet Hepatitis C General - June 6, 2013 Category: Infectious Diseases Source Type: news

Bleeding Risk in Patients with Esophageal Varices Undergoing Transesophageal Echocardiography
ConclusionsTEE can be performed without serious bleeding risk in patients with grade 1 or 2 esophageal varices. (Source: Echocardiography)
Source: Echocardiography - June 6, 2013 Category: Cardiology Authors: Ganesh Pantham, Nisheet Waghray, Douglas Einstadter, Robert S. Finkelhor, Kevin D. Mullen Tags: Original Investigation Source Type: research